Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.

Russo AT, Berhanu A, Bigger CB, Prigge J, Silvera PM, Grosenbach DW, Hruby D.

Vaccine. 2019 Oct 30. pii: S0264-410X(19)31429-X. doi: 10.1016/j.vaccine.2019.10.049. [Epub ahead of print]

2.

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.

Huttner A, Agnandji ST, Combescure C, Fernandes JF, Bache EB, Kabwende L, Ndungu FM, Brosnahan J, Monath TP, Lemaître B, Grillet S, Botto M, Engler O, Portmann J, Siegrist D, Bejon P, Silvera P, Kremsner P, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia.

Lancet Infect Dis. 2018 Jul;18(7):738-748. doi: 10.1016/S1473-3099(18)30165-8. Epub 2018 Apr 5.

3.

IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients.

Echeverría N, Chiodi D, López P, Sanchez Ciceron A, Angulo J, López-Lastra M, Silvera P, Canavesi A, Bianchi C, Colistro V, Cristina J, Hernandez N, Moreno P.

Virol J. 2018 Mar 2;15(1):40. doi: 10.1186/s12985-018-0946-2.

4.

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.

Agnandji ST, Fernandes JF, Bache EB, Obiang Mba RM, Brosnahan JS, Kabwende L, Pitzinger P, Staarink P, Massinga-Loembe M, Krähling V, Biedenkopf N, Fehling SK, Strecker T, Clark DJ, Staines HM, Hooper JW, Silvera P, Moorthy V, Kieny MP, Adegnika AA, Grobusch MP, Becker S, Ramharter M, Mordmüller B, Lell B; VEBCON Consortium, Krishna S, Kremsner PG.

PLoS Med. 2017 Oct 6;14(10):e1002402. doi: 10.1371/journal.pmed.1002402. eCollection 2017 Oct.

5.

Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.

ElSherif MS, Brown C, MacKinnon-Cameron D, Li L, Racine T, Alimonti J, Rudge TL, Sabourin C, Silvera P, Hooper JW, Kwilas SA, Kilgore N, Badorrek C, Ramsey WJ, Heppner DG, Kemp T, Monath TP, Nowak T, McNeil SA, Langley JM, Halperin SA; Canadian Immunization Research Network.

CMAJ. 2017 Jun 19;189(24):E819-E827. doi: 10.1503/cmaj.170074.

6.

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium.

Lancet Infect Dis. 2015 Oct;15(10):1156-1166. doi: 10.1016/S1473-3099(15)00154-1. Epub 2015 Aug 4.

7.

Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.

Berhanu A, Prigge JT, Silvera PM, Honeychurch KM, Hruby DE, Grosenbach DW.

Antimicrob Agents Chemother. 2015 Jul;59(7):4296-300. doi: 10.1128/AAC.00208-15. Epub 2015 Apr 20.

8.

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.

Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA.

N Engl J Med. 2016 Apr 28;374(17):1647-60. doi: 10.1056/NEJMoa1502924. Epub 2015 Apr 1.

9.

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group.

N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1.

10.

Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.

Crickard L, Babas T, Seth S, Silvera P, Koriazova L, Crotty S.

PLoS One. 2012;7(11):e48706. doi: 10.1371/journal.pone.0048706. Epub 2012 Nov 2.

11.

Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques.

Denzler KL, Babas T, Rippeon A, Huynh T, Fukushima N, Rhodes L, Silvera PM, Jacobs BL.

Vaccine. 2011 Dec 6;29(52):9684-90. doi: 10.1016/j.vaccine.2011.09.135. Epub 2011 Oct 12.

12.

Smallpox vaccine safety is dependent on T cells and not B cells.

Gordon SN, Cecchinato V, Andresen V, Heraud JM, Hryniewicz A, Parks RW, Venzon D, Chung HK, Karpova T, McNally J, Silvera P, Reimann KA, Matsui H, Kanehara T, Shinmura Y, Yokote H, Franchini G.

J Infect Dis. 2011 Apr 15;203(8):1043-53. doi: 10.1093/infdis/jiq162.

13.

Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge.

Hirao LA, Draghia-Akli R, Prigge JT, Yang M, Satishchandran A, Wu L, Hammarlund E, Khan AS, Babas T, Rhodes L, Silvera P, Slifka M, Sardesai NY, Weiner DB.

J Infect Dis. 2011 Jan 1;203(1):95-102. doi: 10.1093/infdis/jiq017.

14.

Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys.

Zielinski RJ, Smedley JV, Perera PY, Silvera PM, Waldmann TA, Capala J, Perera LP.

Vaccine. 2010 Oct 8;28(43):7081-91. doi: 10.1016/j.vaccine.2010.08.008. Epub 2010 Aug 20.

15.

A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.

Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, DeTolla LJ, Davis HL, Eisenberg RJ, Cohen GH, Isaacs SN.

Vaccine. 2010 Sep 14;28(40):6627-36. doi: 10.1016/j.vaccine.2010.07.030. Epub 2010 Jul 24.

16.

Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Hooper JW, Ferro AM, Golden JW, Silvera P, Dudek J, Alterson K, Custer M, Rivers B, Morris J, Owens G, Smith JF, Kamrud KI.

Vaccine. 2009 Dec 11;28(2):494-511. doi: 10.1016/j.vaccine.2009.09.133. Epub 2009 Oct 13.

17.

Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes.

Valentin A, Chikhlikar P, Patel V, Rosati M, Maciel M, Chang KH, Silvera P, Felber BK, Pavlakis GN, August JT, Marques ET.

Vaccine. 2009 Jul 30;27(35):4840-9. doi: 10.1016/j.vaccine.2009.05.093. Epub 2009 Jun 17.

18.

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.

Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, Lin S, Peters E, Rhodes L Jr, Spano YE, Silvera PM, Moss B.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10889-94. doi: 10.1073/pnas.0804985105. Epub 2008 Aug 4.

19.

A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.

zur Megede J, Sanders-Beer B, Silvera P, Golightly D, Bowlsbey A, Hebblewaite D, Sites D, Nieves-Duran L, Srivastava R, Otten GR, Rabussay D, Zhang L, Ulmer JB, Barnett SW, Donnelly JJ.

AIDS Res Hum Retroviruses. 2008 Aug;24(8):1103-16. doi: 10.1089/aid.2008.0055.

20.

Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid.

Boyer JD, Robinson TM, Kutzler MA, Vansant G, Hokey DA, Kumar S, Parkinson R, Wu L, Sidhu MK, Pavlakis GN, Felber BK, Brown C, Silvera P, Lewis MG, Monforte J, Waldmann TA, Eldridge J, Weiner DB.

Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18648-53. Epub 2007 Nov 13.

21.

Macaques co-immunized with SIVgag/pol-HIVenv and IL-12 plasmid have increased cellular responses.

Robinson TM, Sidhu MK, Pavlakis GN, Felber BK, Silvera P, Lewis MG, Eldridge J, Weiner DB, Boyer JD.

J Med Primatol. 2007 Aug;36(4-5):276-84.

PMID:
17669216
22.

Preparation and characterization of new challenge stocks of SIVmac32H J5 following rapid serial passage of virus in vivo.

Ferguson D, Wade-Evans A, Elsley W, Sangster R, Silvera P, MacManus S, Davis G, Corcoran T, Berry N, Brown S, Jenkins A, Cowie J, Sethi M, Hull R, Stebbings R, Lines J, Norley S, Stott EJ, Almond N.

J Med Primatol. 2007 Jun;36(3):131-42.

PMID:
17517087
23.

DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge.

Nigam P, Earl PL, Americo JL, Sharma S, Wyatt LS, Edghill-Spano Y, Chennareddi LS, Silvera P, Moss B, Robinson HL, Amara RR.

Virology. 2007 Sep 15;366(1):73-83. Epub 2007 May 16.

24.

Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.

McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, Schnell MJ.

J Infect Dis. 2007 Apr 1;195(7):980-8. Epub 2007 Feb 20.

PMID:
17330788
25.

DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques.

Chikhlikar P, Barros de Arruda L, Maciel M, Silvera P, Lewis MG, August JT, Marques ET.

PLoS One. 2006 Dec 27;1:e135.

26.

Subunit recombinant vaccine protects against monkeypox.

Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G.

J Immunol. 2006 Aug 15;177(4):2552-64.

27.

Persistent anti-gag, -Nef, and -Rev IgM levels as markers of the impaired functions of CD4+ T-helper lymphocytes during SIVmac251 infection of cynomolgus macaques.

Régulier EG, Panemangalore R, Richardson MW, DeFranco JJ, Kocieda V, Gordon-Lyles DC, Silvera P, Khalili K, Zagury JF, Lewis MG, Rappaport J.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):1-11.

PMID:
16123674
28.

Interleukin-15 increases effector memory CD8+ t cells and NK Cells in simian immunodeficiency virus-infected macaques.

Mueller YM, Petrovas C, Bojczuk PM, Dimitriou ID, Beer B, Silvera P, Villinger F, Cairns JS, Gracely EJ, Lewis MG, Katsikis PD.

J Virol. 2005 Apr;79(8):4877-85.

29.

Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.

Quinnan GV Jr, Yu XF, Lewis MG, Zhang PF, Sutter G, Silvera P, Dong M, Choudhary A, Sarkis PT, Bouma P, Zhang Z, Montefiori DC, Vancott TC, Broder CC.

J Virol. 2005 Mar;79(6):3358-69.

30.

Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.

Silvera P, Savary JR, Livingston V, White J, Manson KH, Wyand MH, Salk PL, Moss RB, Lewis MG.

Vaccine. 2004 Dec 21;23(6):827-39.

PMID:
15542208
31.

T-cell receptor excision circles (TREC) in SHIV 89.6p and SIVmac251 models of HIV-1 infection.

Richardson MW, Sverstiuk AE, Silvera P, Greenhouse J, Lisziewicz J, Lori F, Khalili K, Lewis MG, Rappaport J.

DNA Cell Biol. 2004 Jan;23(1):1-13.

PMID:
14965468
32.

High attenuation and immunogenicity of a simian immunodeficiency virus expressing a proteolysis-resistant inhibitor of NF-kappaB.

Quinto I, Puca A, Greenhouse J, Silvera P, Yalley-Ogunro J, Lewis MG, Palmieri C, Trimboli F, Byrum R, Adelsberger J, Venzon D, Chen X, Scala G.

J Biol Chem. 2004 Jan 16;279(3):1720-8. Epub 2003 Oct 30.

33.

Patterns of gene expression in peripheral blood mononuclear cells of rhesus macaques infected with SIVmac251 and exhibiting differential rates of disease progression.

Vahey MT, Nau ME, Taubman M, Yalley-Ogunro J, Silvera P, Lewis MG.

AIDS Res Hum Retroviruses. 2003 May;19(5):369-87.

PMID:
12803996
34.

Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses.

Richardson MW, Mirchandani J, Silvera P, Régulier EG, Capini C, Bojczuk PM, Hu J, Gracely EJ, Boyer JD, Khalili K, Zagury JF, Lewis MG, Rappaport J.

DNA Cell Biol. 2002 Sep;21(9):637-51.

PMID:
12396606
35.

Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.

Tryniszewska E, Nacsa J, Lewis MG, Silvera P, Montefiori D, Venzon D, Hel Z, Parks RW, Moniuszko M, Tartaglia J, Smith KA, Franchini G.

J Immunol. 2002 Nov 1;169(9):5347-57.

36.

Mechanisms of protection induced by attenuated simian immunodeficiency virus.

Stebbings RJ, Almond NM, Stott EJ, Berry N, Wade-Evans AM, Hull R, Lines J, Silvera P, Sangster R, Corcoran T, Rose J, Walker KB.

Virology. 2002 May 10;296(2):338-53.

37.

Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein.

Silvera P, Richardson MW, Greenhouse J, Yalley-Ogunro J, Shaw N, Mirchandani J, Khalili K, Zagury JF, Lewis MG, Rappaport J.

J Virol. 2002 Apr;76(8):3800-9.

38.

Specific proliferative T cell responses and antibodies elicited by vaccination with simian immunodeficiency virus Nef do not confer protection against virus challenge.

Wade-Evans AM, Stott J, Hanke T, Stebbings R, Berry N, Lines J, Sangster R, Silvera P, Walker B, MacManus S, Davis G, Cowie J, Arnold C, Hull R, Almond N.

AIDS Res Hum Retroviruses. 2001 Nov 1;17(16):1517-26.

PMID:
11709096
39.

In situ hybridization and immunolabelling study of the early replication of simian immunodeficiency virus (SIVmacJ5) in vivo.

Cantó-Nogués C, Jones S, Sangster R, Silvera P, Hull R, Cook R, Hall G, Walker B, Stott EJ, Hockley D, Almond N.

J Gen Virol. 2001 Sep;82(Pt 9):2225-34.

PMID:
11514733
40.
41.

Control of SIV rebound through structured treatment interruptions during early infection.

Lori F, Lewis MG, Xu J, Varga G, Zinn DE Jr, Crabbs C, Wagner W, Greenhouse J, Silvera P, Yalley-Ogunro J, Tinelli C, Lisziewicz J.

Science. 2000 Nov 24;290(5496):1591-3.

42.

Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques.

Silvera P, Racz P, Racz K, Bischofberger N, Crabbs C, Yalley-Ogunro J, Greenhouse J, Jiang JB, Lewis MG.

AIDS Res Hum Retroviruses. 2000 May 20;16(8):791-800.

PMID:
10826485
43.

The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus.

Almond N, Jenkins A, Jones S, Arnold C, Silvera P, Kent K, Mills KH, Stott EJ.

J Gen Virol. 1999 Sep;80 ( Pt 9):2375-82.

PMID:
10501490
44.

Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection.

Stebbings R, Stott J, Almond N, Hull R, Lines J, Silvera P, Sangster R, Corcoran T, Rose J, Cobbold S, Gotch F, McMichael A, Walker B.

AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1187-98.

PMID:
9737590
45.

Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus.

Stott EJ, Almond N, Kent K, Walker B, Hull R, Rose J, Silvera P, Sangster R, Corcoran T, Lines J, Silvera K, Luciw P, Murphy-Corb M, Momin P, Bruck C.

J Gen Virol. 1998 Mar;79 ( Pt 3):423-32.

PMID:
9519819
46.

Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum.

Almond N, Rose J, Sangster R, Silvera P, Stebbings R, Walker B, Stott EJ.

J Gen Virol. 1997 Aug;78 ( Pt 8):1919-22.

PMID:
9266988
47.

Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR-CD8- thymocytes.

Godfrey DI, Kinder SJ, Silvera P, Baxter AG.

J Autoimmun. 1997 Jun;10(3):279-85.

PMID:
9218755
48.

Mechanisms of protection induced by attenuated simian immunodeficiency virus. IV. Protection against challenge with virus grown in autologous simian cells.

Almond N, Corcoran T, Hull R, Walker B, Rose J, Sangster R, Silvera K, Silvera P, Cranage M, Rud E, Stott EJ.

J Med Primatol. 1997 Feb-Apr;26(1-2):34-43.

PMID:
9271187
49.

Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques.

Gallimore A, Cranage M, Cook N, Almond N, Bootman J, Rud E, Silvera P, Dennis M, Corcoran T, Stott J, et al.

Nat Med. 1995 Nov;1(11):1167-73.

PMID:
7584989
50.

Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H.

Chan WL, Rodgers A, Grief C, Almond N, Ellis S, Flanagan B, Silvera P, Bootman J, Stott J, Kent K, et al.

AIDS. 1995 Mar;9(3):223-8.

PMID:
7755909

Supplemental Content

Loading ...
Support Center